Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on ARS Pharmaceuticals and raised its price target from $21 to $25, indicating confidence in the company's future performance.
September 20, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has increased its price target for ARS Pharmaceuticals from $21 to $25 while maintaining an 'Outperform' rating, suggesting positive expectations for the company's stock performance.
The increase in price target from $21 to $25 by Leerink Partners, along with the maintained 'Outperform' rating, indicates a strong positive outlook for ARS Pharmaceuticals. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100